|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
|
|---|---|---|---|
| Other operating income | |||
| Total operating income | |||
| Sales and marketing | |||
| Research and development | |||
| General and administrative | |||
| Goodwill impairment loss | |||
| Total operating expenses | |||
| Operating loss | |||
| Financial expenses | |||
| Financial income | |||
| Financial gain (loss) | |||
| Net loss before tax | |||
| Income tax | |||
| Net loss for the period | |||
| Loss per share (€/share) | |||
| Weighted average number of outstanding shares used for computing basic loss per share (in shares) | |||
| Weighted average number of outstanding shares used for computing diluted loss per share (in shares) | |||
| Basic loss per share (in euro per share) | |||
| Diluted loss per share (in euro per share) |
Loading...
